They only have a short note in prospectus about Medicare reimbursement. Their is no mention of lower reimbursement for EPIFIX, their primary product. Their is no mention of revenue in the SEC filings. It appears that reimbursement under the Nov. 2013 CMS ruling will be lower than their January CMS Q4131 rate. Silence cannot be good news. If reimbursement is lower, they will not be profitable in 2014
Ah! I see the 12/5 statement now but strange it was not in filing. It is material. So that seems OK just the FDA warning letter on $15MM of sales that may be taken off market. Hate any company with CMS reimbursement issues but that is life.